Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
A central regulator of this epithelial barrier is the intestinal microbiota [21]
Several important considerations apply: Individuals with active or severe gastrointestinal disease may experience worsening symptoms due to the gastrointestinal side effects of GLP-1 medications The slowed gastric emptying caused by these drugs could theoretically exacerbate symptoms in people with strictures or obstructive complications of Crohn's disease Weight loss associated with GLP-1 therapy may be inappropriate in patients with Crohn's disease who are already experiencing malnutrition or unintentional weight loss The interaction between GLP-1 medications and the inflammatory processes in IBD is not fully understood Clinical decision-making should involve a thorough assessment of disease activity, nutritional status, presence of complications (such as strictures or fistulas), and the primary indication for GLP-1 therapy
Birth control pills might not work as well
Find out more about tirzepatide and semaglutide, and which one might be best for you in our guide
